HLB: Shares Up Sharply Over Three Months While Filed Results Still Show Large Losses

Thesis

The data supports a story of rising share price momentum: +41.2% in one month, +73.1% in three months and +20.0% over one year. The price sits below the 52-week high of ₩69,200 and well above the low of ₩24,150. The financial statements do not yet support the valuation with profits, since the company has posted operating losses in every year from 2021 to 2025 and in the trailing period. Revenue has grown in recent years, but it is small relative to the losses. News headlines mention a Lypic TO addition to NCCN guidelines after FDA approval, an upcoming integrated IR day on the 15th, and subsidiary research wins. The data does not show how these translate into future revenue. Investor flow, foreign ownership and short balance data are not available, so we cannot say who is driving the price move.

Business overview

HLB is a Biotech & Pharma company listed on KOSDAQ since 1996-07-27, founded in 1985, with 131,438,096 listed shares. The CEO is listed as 김홍철. Market cap is ₩5,835.9B and enterprise value is ₩5,865.5B. Annual revenue was ₩69.8B in 2021, ₩179.7B in 2022, ₩42.9B in 2023, ₩68.1B in 2024 and ₩84.2B in 2025, so the revenue history is uneven. The data does not describe the company's products or pipeline beyond the news headlines.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Report history

1. Oct 20, 2026Update noteNewsHLB Outlines Group Mid-to-Long-Term Strategy After FDA Approval News; Financials Unchanged
2. Oct 13, 2026InitiationHLB: Shares Up Sharply Over Three Months While Filed Results Still Show Large Losses